P21 is studied in the context of neuroscience and cognitive research. Activates downstream CNTF signaling without the appetite-suppressing effect of full-length CNTF; raises BDNF expression, proposed to inhibit GSK-3β via the TrkB/PI3K/Akt pathway and thereby reduce tau hyperphosphorylation.
A preclinical research tool in Alzheimer's and tauopathy models for studying neurogenesis and tau-related pathology; the evidence base remains thin and concentrated in a small number of laboratories.
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Studies on neuroscience-related peptides are predominantly preclinical.
Specific study references will be added for this product. For current literature, independent research (e.g. via PubMed) is recommended.
We reply personally – via email or Telegram.